Generate Biomedicines, Inc. reports news tied to its clinical-stage biotechnology pipeline, generative biology platform, and public-company disclosures. Recurring updates cover financial results, business updates, clinical program progress for GB-0895, GB-4362, and GB-5267, regulatory designations, and collaborations connected to its protein therapeutic candidates.
Company news also includes shareholder voting matters, capital-structure disclosures, and clinical or regulatory disclosures following its transition to a Nasdaq-listed public company.
Generate Biomedicines (GENB) will have members of its management team present at two investor conferences in November 2026. The Guggenheim 3rd Annual Healthcare Innovation Conference presentation in Boston is scheduled for November 9 at 1 p.m. ET. The Jefferies Global Healthcare Conference presentation in London is scheduled for November 16 at 10:30 a.m. ET.
Live webcasts will be accessible through the company’s investor website, with replays available for 90 days following each event.
Generate Biomedicines (GENB) entered a collaboration and license agreement with Zealand Pharma to develop protein therapeutics, receiving $30 million upfront.
The collaboration initially covers two programs for obesity and other metabolic diseases, with an option to add a third. The companies intend to design proteins with multiple biological functions using Generate’s generative AI platform and Zealand’s metabolic-health expertise. Generate will lead research through selection of lead candidates; Zealand will handle subsequent clinical development, regulatory submissions and worldwide commercialization.
Generate is eligible for up to nearly $1.2 billion in total milestones, including up to $35 million in early preclinical milestones, plus potential development, regulatory and commercial milestones. It will also receive tiered royalties on future worldwide net sales of any commercialized collaboration products.
Generate Biomedicines (NASDAQ: GENB) and Roswell Park have dosed the first patient in a clinical trial of GB-5267 for ovarian cancer. The first-in-human phase 1 trial, NCT07489287, evaluates safety and tolerability and is recruiting patients whose disease has returned after treatment or does not respond to platinum-based chemotherapy.
GB-5267 is an investigational therapy using a patient’s own genetically engineered T cells, immune cells capable of killing cancer cells. It targets MUC16, an antigen over-expressed in more than 80% of ovarian tumors. Generate designed the therapy with AI to improve tumor-cell killing, T-cell expansion and sustained activity. The study does not require lymphodepletion, chemotherapy used to reduce existing immune cells before treatment. Delivery will be both intravenous and into the peritoneal cavity, the abdominal space where ovarian cancer spreads.
Generate Biomedicines (GENB)/b) will participate in multiple healthcare investor conferences in New York in September 2026.Management presentations are scheduled at the Cantor Global Healthcare Conference on September 9 at 3:55 p.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:00 a.m. ET, the Goldman Sachs Life Sciences Symposium on September 15 at 9:05 a.m. ET, the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 10:30 a.m. ET, and Bernstein Insights Healthcare Leaders and Disruptors on September 23 at 8:00 a.m. ET.
Live webcasts and 90‑day replays will be available via the Investors “Events & Presentations” page on the company’s website, which, along with its LinkedIn and X accounts, may be used for material disclosures.
Generate Biomedicines (NASDAQ: GENB) reported Q2 2026 collaboration revenue of $6.3 million, down from $10.1 million a year earlier, and a net loss of $67.3 million versus $56.7 million. Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026, which the company believes will fund its current operating plan into the first half of 2028.
Clinical progress included advancing global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials of GB-0895 in severe asthma, Phase 1b COPD data and asthma data to be presented at ERS 2026, and enrollment of the first cohort in the Phase 1 study of GB-4362, an FDA Fast Track MMAE neutralizer. Novartis moved an AI-designed biologic from The Generate Platform into its preclinical pipeline, and a Phase 1 trial of GB-5267 CAR T in ovarian cancer is recruiting.
AdvanCell signed a long-term lease for the entire ~128,000 square foot 1 Corporate Drive building at IQHQ's Innovation Park in Andover, Massachusetts, bringing newly constructed Phase 2 to 100% leased. The 340,000 square foot campus hosts advanced life science manufacturing, amenities, and infrastructure.
AdvanCell, a clinical-stage radiopharmaceutical company, will use the site as its global headquarters and first U.S. manufacturing facility to scale Lead-212 targeted alpha therapy production, including lead candidate 212Pb-ADVC001 for prostate cancer. Innovation Park also includes Generate Biomedicines (NASDAQ: GENB), which completed a ~$400 million IPO in February 2026.
Generate Biomedicines (NASDAQ: GENB) plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026.
A live webcast and an archived replay are expected to be available on the company’s investor website under Events and Presentations.
Generate Biomedicines (NASDAQ: GENB) reported Q1 2026 results and clinical progress on May 7, 2026. Cash, cash equivalents, and marketable securities totaled $516.6M as of March 31, 2026, reflecting $369.3M net IPO proceeds. Revenue was $7.2M; net loss was $61.7M. SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials for GB-0895 continue; GB-4362 sites activated with FDA Fast Track designation and mid-2026 dosing expected; GB-5267 first dosing expected in H2 2026. Generate expects cash to fund operations into H1 2028 and may require additional capital for longer-term operations.
Generate Biomedicines (Nasdaq: GENB) priced an initial public offering of 25,000,000 shares at $16.00 per share, implying gross proceeds of $400 million before underwriting discounts and offering expenses. The underwriters have a 30‑day option for an additional 3,750,000 shares.
Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, and the offering is expected to close on March 2, 2026, subject to customary closing conditions. The SEC declared the registration effective on February 26, 2026.